中文
Products

CP / MP IgM Antibody Test Kit

CP / MP IgM Antibody Test Kit (Quantum Dots)

Intended Use

For the in vitro quantitative detection of Chlamydia pneumoniae (CP) IgM antibody and Mycoplasma pneumoniae (MP) IgM antibody in human serum, plasma, or whole blood samples.

CP / MP IgM Antibody Test Kit

Clinical Department

Clinical Laboratory, Respiratory Medicine Department, Paediatrics Department, Outpatient Department, Emergency Department, Infectious Diseases Department, etc.

Product Parameters Clinical application

[Product Name]CP / MP IgM Antibody Test Kit

[Sample Type]serum, plasma or whole blood

[Intended Use]
For the in vitro quantitative detection of Chlamydia pneumoniae (CP) IgM antibody and Mycoplasma pneumoniae (MP) IgM antibody in human serum, plasma, or whole blood samples.

[Clinical Department]
Clinical Laboratory, Respiratory Medicine Department, Paediatrics Department, Outpatient Department, Emergency Department, Infectious Diseases Department, etc.


Product Parameters

Item

CP/MP IgM Ab (Quantum Dots)

Test Time

15-20min

Sample Type

serum, plasma or whole blood

Sensitivity

/

Storage Condition

4-30℃

Packing Specification

1 Test/Kit; 2 Tests/Kit; 5 Tests/Kit; 10 Tests/Kit; 20 Tests/Kit; 40 Tests/Kit


CP and MP are common atypical pathogens responsible for respiratory diseases such as community-acquired pneumonia and upper respiratory tract infections. Their clinical manifestations lack specificity and are liable to be confused with infections caused by common bacteria and viruses.

MP IgM antibodies emerge 2–3 weeks post-infection, indicating recent or acute infection, and can be clinically used as an early auxiliary diagnostic indicator for Chlamydophila pneumoniae infection in adults and adolescents.

CP IgM antibodies appear 1 week after infection, which is of great value for the diagnosis of acute mycoplasmal pneumonia in children and adolescents, and is suitable for use in primary medical institutions.

1. Combined testing allows simultaneous identification of CP and MP, eliminating diagnostic blind spots associated with single-pathogen testing.

2. By synchronously analysing changes in the titres of IgM antibodies against the two pathogens, combined testing can determine whether an infection is in the acute or recovery phase.

3. Combined testing enhances the capacity for early detection in children, adolescents and immunocompromised individuals, providing reliable support for timely intervention and precision treatment, and reducing the risk of complications and severe illness.


微信公众平台

官网二维码